Arvinas (ARVN) Stock Forecast & Price Target

$24.74

+0.38 (+1.56%)

(As of 09/27/2024 ET)

Arvinas - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
2

Buy
14

Based on 16 Wall Street analysts who have issued ratings for Arvinas in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 2 have given a hold rating, and 14 have given a buy rating for ARVN.

Consensus Price Target

$57.50
132.42% Upside

According to the 16 analysts' twelve-month price targets for Arvinas, the average price target is $57.50. The highest price target for ARVN is $90.00, while the lowest price target for ARVN is $20.00. The average price target represents a forecasted upside of 132.42% from the current price of $24.74.

Get the Latest News and Ratings for ARVN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Arvinas and its competitors.

ARVN Analyst Ratings Over Time

Type	Current Forecast 9/30/23 to 9/29/24	1 Month Ago 8/31/23 to 8/30/24	3 Months Ago 7/2/23 to 7/1/24	1 Year Ago 9/30/22 to 9/30/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)	12 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$57.50	$58.33	$61.13	$64.07
Forecasted Upside	132.42% Upside	122.99% Upside	135.31% Upside	226.23% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

NOTICE: You have until Tuesday, November 19th (Ad)

On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...

Click here for the ticker >>>

ARVN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Arvinas Stock vs. The Competition

Type	Arvinas	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	132.42% Upside	818.50% Upside	6.16% Upside
News Sentiment Rating	Positive News See Recent ARVN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/9/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight
8/1/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$87.00 ➝ $87.00	+216.25%
7/31/2024	Barclays 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$60.00 ➝ $48.00	+78.44%
7/31/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$70.00 ➝ $50.00	+84.57%
7/30/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$57.00 ➝ $57.00	+110.41%
5/9/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$63.00 ➝ $60.00	+83.43%
Get the Latest News and Ratings for ARVN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.
5/8/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$72.00 ➝ $68.00	+101.06%
3/25/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$65.00	+57.73%
2/28/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$89.00 ➝ $90.00	+87.46%
2/22/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/14/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$36.00 ➝ $55.00	+15.14%
2/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$70.00	+68.67%
12/6/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$32.00 ➝ $40.00	+38.07%
11/20/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$40.00	+91.20%
11/13/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $20.00	+31.06%
10/23/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$70.00 ➝ $55.00	+278.01%
2/24/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$81.00 ➝ $61.00	+92.01%
11/22/2022	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$89.00 ➝ $74.00	+71.77%
10/25/2022	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Z. Jallah Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:29 PM ET.

ARVN Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Arvinas is $57.50, with a high forecast of $90.00 and a low forecast of $20.00.
: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARVN shares.
: According to analysts, Arvinas's stock has a predicted upside of 132.42% based on their 12-month stock forecasts.
: Arvinas has been rated by research analysts at Barclays, Cantor Fitzgerald, HC Wainwright, Oppenheimer, and Wedbush in the past 90 days.
: Analysts like Arvinas more than other "medical" companies. The consensus rating score for Arvinas is 2.88 while the average consensus rating score for "medical" companies is 2.78. Learn more on how ARVN compares to other companies.